These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 276626)

  • 1. Cell-surface major glycoprotein of BALB/c mouse plasmacytoma 58-8 cells.
    Tokuyama H; Migita S
    J Natl Cancer Inst; 1978 Jul; 61(1):203-8. PubMed ID: 276626
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteration of cell-surface antigenicity of the mouse plasmacytoma. II. Lack of correlation between synthesis of myeloma protein and alteration of surface antigen.
    Ohno S; Natsu-ume-Sakai S; Migita S
    J Natl Cancer Inst; 1977 Feb; 58(2):229-37. PubMed ID: 833874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered cell surface organization of gangliosides and sialylglycoproteins of mouse metastatic melanoma variant lines selected in vivo for enhanced lung implantation.
    Yogeeswaran G; Stein BS; Sebastian H
    Cancer Res; 1978 May; 38(5):1336-44. PubMed ID: 639064
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of cell-surface antigenicity of the mouse plasmacytoma. I. Immunologic characterization of surface antigens masked during successive transplantations.
    Ono S; Natsu-ume S; Migita S
    J Natl Cancer Inst; 1975 Sep; 55(3):569-77. PubMed ID: 51090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts.
    Forni G; Comoglio PM
    Br J Cancer; 1974 Oct; 30(4):365-9. PubMed ID: 4447779
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
    Braun DP; Dray S
    Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma-cell and tumor-associated membrane antigens of mouse plasmacytoma MOPC-315 and MOPC-460.
    Comoglio PM; Forni G
    Int J Cancer; 1973 Nov; 12(3):613-25. PubMed ID: 4134007
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyadenylation of 35S RNA in vitro by a cytoplasmic particulate fraction from mouse myeloma.
    Wong-Staal F; Saxinger WC; Gallo RC; Gillespie DH
    Biochem Biophys Res Commun; 1976 Apr; 69(3):599-607. PubMed ID: 1267806
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
    Hiramoto RN; Ghanta VK
    Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
    [No Abstract]   [Full Text] [Related]  

  • 14. An analysis of T lymphocyte subsets in tumour-transplanted mice on the basis of Lyt antigenic markers and functions.
    Lala PK; McKenzie IF
    Immunology; 1982 Dec; 47(4):663-77. PubMed ID: 6982847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary observations on immunity in BALB-c mice to myeloma tumor of BALB-c origin.
    Shearer WT; Graff RJ; Eisen HN
    Transplantation; 1972 Mar; 13(3):345-7. PubMed ID: 5021442
    [No Abstract]   [Full Text] [Related]  

  • 16. Isolation, purification, and characterization of a mouse plasmacytoma cell surface glycoprotein involved in the resistance of the tumor cells to immune destruction.
    Rosenstein Y; Theelen M; Sánchez I; Celis E
    J Natl Cancer Inst; 1985 Mar; 74(3):609-16. PubMed ID: 3871874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated antigen (TAA) and anti-TAA antibodies in the serum of BALB-c mice with plasmacytomas.
    Kolb JP; Poupon MF; Lespinats G
    J Natl Cancer Inst; 1974 Mar; 52(3):723-7. PubMed ID: 4826560
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of murine plasmocytoma tumours with antibody activity by their respective specific antigens.
    Paraf A; Guérin-Marchand C; Aubry J; Dubert JM
    Ann Immunol (Paris); 1975; 126C(4):411-21. PubMed ID: 55094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive versus augmenting effect of the same pretreatment regimen in two murine tumor systems with distinct effector mechanisms.
    Fufiwara H; Hamaoka T; Kitagawa M
    Gan; 1978 Dec; 69(6):793-803. PubMed ID: 312225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.